Evidence map›Paper›PMID 18559532›Full record

ArticleCancer research2008

Human T-cell leukemia virus I tax protein sensitizes p53-mutant cells to DNA damage.

Valia T Mihaylova, Allison M Green, Moshe Khurgel, Oliver J Semmes, Gary M Kupfer

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Valia T MihaylovaDepartments of Microbiology, University of Virginia Health System, Charlottesville, Virginia, USA.
Allison M Green
Moshe Khurgel
Oliver J Semmes
Gary M Kupfer
Yale University · USEastern Virginia Medical School · USUniversity of Virginia Health System · US

Funding

TRAINING IN CELL AND MOLECULAR BIOLOGYT32GM008136 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI STUKENBERG, P. TODD · 1985 to 2020
$8.5M
The Fanconi Anemia Core and D2 ComplexesR01HL063776 · NHLBI · YALE UNIVERSITY · PI KUPFER, GARY M. · 2000 to 2014
$5.3M
NHLBI NIH HHS R01 HL063776NIGMS NIH HHS T32 GM008136
6 · The paper itself

Abstract

Mutations in p53 are a common cause of resistance of cancers to standard chemotherapy and, thus, treatment failure. Reports have shown that Tax, a human T-cell leukemia virus type I encoded protein that has been associated with genomic instability and perturbation of transcription and cell cycle, sensitizes HeLa cells to UV treatment. The extent to which Tax can sensitize cells and the mechanism by which it exerts its effect are unknown. In this study, we show that Tax sensitizes p53-mutant cells to a broad range of DNA-damaging agents, including mitomycin C, a bifunctional alkylator, etoposide, a topoisomerase II drug, and UV light, but not ionizing radiation, a double-strand break agent, or vinblastine, a tubulin poison. Tax caused hypersensitivity in all p53-deleted cell lines and several, but not all, mutant-expressed p53-containing cell lines, while unexpectedly being protective in p53 wild-type (wt) cells. The effect observed in p53-deleted lines could be reversed for this by transfection of wt p53. We also show that Tax activates a p53-independent proapoptotic program through decreased expression of the retinoblastoma protein and subsequent increased E2F1 expression. The expression of several proapoptotic proteins was also induced by Tax, including Puma and Noxa, culminating in a substantial increase in Bax dimerization. Our results show that Tax can sensitize p53-mutant cells to DNA damage while protecting p53 wt cells, a side benefit that might result in reduced toxicity in normal cells. Such studies hold the promise of a novel adjunctive therapy that could make cancer chemotherapy more effective.

Indexed as

AnimalsAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicApoptosisApoptosis Regulatory Proteinsbcl-2-Associated X ProteinCell CycleCells, CulturedDimerizationDNA DamageEtoposideFibroblastsGene Products, taxHumansImmunoblottingLuciferasesAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicApoptosis Regulatory ProteinsBAX protein, humanBax protein, mouseBBC3 protein, humanbcl-2-Associated X ProteinEtoposideGene Products, taxLuciferasesMitomycinPMAIP1 protein, humanPmaip1 protein, mouseProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2PUMA protein, mousetax protein, Human T-lymphotrophic virus 1Tumor Suppressor Protein p53Tumor Suppressor ProteinsVinblastine

Identifiers

PMID18559532
PMCPMC5939382
OpenAlexW2126122588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.